Hanmi Pharm exports NASH treatment technology worth over 1 trillion KRW to US MSD
[Asia Economy Reporter Moon Hyewon] Hanmi Pharmaceutical announced on the 4th that it has licensed its non-alcoholic steatohepatitis (NASH) treatment technology to the US company MSD for over 1 trillion won.
The total technology export amount is $870 million (approximately 1.0387 trillion won). Among this, the non-refundable signing fee is $10 million (approximately 1.19 billion won), and milestone payments totaling $860 million are expected to be received according to the clinical development stages.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Hanmi Pharmaceutical's NASH treatment is 'Epinofeglutide,' which applies Hanmi's drug efficacy duration technology 'Lapscovery,' with the development code HM12525A. The contract territory covers the entire world except South Korea, where Hanmi Pharmaceutical retains the rights for sales and development domestically, while MSD leads development and commercialization in other regions.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
